Unicycive Therapeutics, Inc. Cash And Cash Equivalents At Carrying Value

Quick Answer

Unicycive Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $29.20 million for the year ending 2025.

  • Unicycive Therapeutics, Inc. showed an increase of +11.7% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
  • This data is from Unicycive Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
  • XBRL data for this metric is available from 2021 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 4 years of available data (2021 to 2025), Unicycive Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 76.1%.
  • Historical annual values: Fiscal year 2025: $29.20 million | Fiscal year 2024: $26.14 million | Fiscal year 2022: $455.0 thousand | Fiscal year 2021: $16.58 million.
  • Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: